EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma

Shawn L Hervey-Jumper, Yalan Zhang, Joanna J Phillips, Ramin A Morshed, Jacob S Young iD, Lucie McCoy iD, Marisa Lafontaine iD, Tracy Luks, Simon Ammanuel, Sofia Kakaizada, Andrew Egladyous, Andrew Gogos iD und 24 weitere

Journal of Clinical Oncology · 10.04.2023 · 41 (11) · 2029-2042

DOI: 10.1200/jco.21.02929 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2023. Verfasst von Shawn L Hervey-Jumper und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Oligodendroglioma, Brain Neoplasms, Glioma, Astrocytoma. Die Arbeit wurde bisher 170-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCCDPHP CDC HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE In patients with diffuse low-grade glioma (LGG), the extent of surgical tumor resection (EOR) has a controversial role, in part because a randomized clinical trial with different levels of EOR is not feasible. METHODS In a 20-year retrospective cohort of 392 patients with IDH-mutant grade 2 glioma, we analyzed the combined effects of volumetric EOR and molecular and clinical factors on overall survival (OS) and progression-free survival by recursive partitioning analysis. The OS results were validated in two external cohorts (n = 365). Propensity score analysis of the combined cohorts (n = 757) was used to mimic a randomized clinical trial with varying levels of EOR. RESULTS Recursive partitioning analysis identified three survival risk groups. Median OS was shortest in two subsets of patients with astrocytoma: those with postoperative tumor volume (TV) > 4.6 mL and those with preoperative TV > 43.1 mL and postoperative TV ≤ 4.6 mL. Intermediate OS was seen in patients with astrocytoma who had chemotherapy with preoperative TV ≤ 43.1 mL and postoperative TV ≤ 4.6 mL in addition to oligodendroglioma patients with either preoperative TV > 43.1 mL and residual TV ≤ 4.6 mL or postoperative residual volume > 4.6 mL. Longest OS was seen in astrocytoma patients with preoperative TV ≤ 43.1 mL and postoperative TV ≤ 4.6 mL who received no chemotherapy and oligodendroglioma patients with preoperative TV ≤ 43.1 mL and postoperative TV ≤ 4.6 mL. EOR ≥ 75% improved survival outcomes, as shown by propensity score analysis. CONCLUSION Across both subtypes of LGG, EOR beginning at 75% improves OS while beginning at 80% improves progression-free survival. Nonetheless, maximal resection with preservation of neurological function remains the treatment goal. Our findings have implications for surgical strategies for LGGs, particularly oligodendroglioma. [Media: see text]

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligodendrogliomaBrain NeoplasmsGliomaAstrocytomaHumansRetrospective StudiesNeurosurgical ProceduresTreatment Outcome

Autor:innen und Institutionen

  • Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
  • Department of Pathology, University of California, San Francisco, San Francisco, CA.
  • Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA.
  • Department of Neurology, University of California, San Francisco, San Francisco, CA.
  • Department of Neurological Surgery, St Olavs University Hospital, Trondheim, Norway.
  • Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, University of Gothenburg, Sahlgrenska Academy, Gothenburg, Sweden.

ORCID-Profile: Jacob S Young, Lucie McCoy, Marisa Lafontaine, Andrew Gogos, Javier Villanueva-Meyer, Gayathri Warrier, Jason Crane, Jennie W Taylor, Nicholas Butowski, Edward Chang, Asgeir S Jakola, Ole Solheim, Annette M Molinaro

Förderung

  • NCI NIH HHS
  • NCCDPHP CDC HHS
  • NCRR NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Hervey-Jumper, S. L., Zhang, Y., Phillips, J. J., Morshed, R. A., Young, J. S., McCoy, L., Lafontaine, M., Luks, T., Ammanuel, S., Kakaizada, S., Egladyous, A., Gogos, A., Villanueva-Meyer, J., Shai, A., Warrier, G., Rice, T., Crane, J., Wrensch, M., Wiencke, J. K., …, & Molinaro, A. M. (2023). Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. Journal of Clinical Oncology, 41(11), 2029-2042. https://doi.org/10.1200/jco.21.02929

Vancouver

Hervey-Jumper SL, Zhang Y, Phillips JJ, Morshed RA, Young JS, McCoy L, et al. Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. Journal of Clinical Oncology. 2023;41(11):2029-2042. doi:10.1200/jco.21.02929

BibTeX
@article{HerveyJumper2023,
  author = {Hervey-Jumper, Shawn L and Zhang, Yalan and Phillips, Joanna J and Morshed, Ramin A and Young, Jacob S and McCoy, Lucie and Lafontaine, Marisa and Luks, Tracy and Ammanuel, Simon and Kakaizada, Sofia and Egladyous, Andrew and Gogos, Andrew and Villanueva-Meyer, Javier and Shai, Anny and Warrier, Gayathri and Rice, Terri and Crane, Jason and Wrensch, Margaret and Wiencke, John K and Daras, Mariza and Oberheim Bush, Nancy Ann and Taylor, Jennie W and Butowski, Nicholas and Clarke, Jennifer and Chang, Susan and Chang, Edward and Aghi, Manish and Theodosopoulos, Philip and McDermott, Michael and Jakola, Asgeir S and Kavouridis, Vasileios K and Nawabi, Noah and Solheim, Ole and Smith, Timothy and Berger, Mitchel S and Molinaro, Annette M},
  title = {Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {11},
  pages = {2029--2042},
  doi = {10.1200/jco.21.02929}
}
Kostenlos starten →